Sutro Biopharma Inc (STRO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Sutro Biopharma Inc (STRO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10856
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:39
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sutro Biopharma Inc (Sutro Biopharma), formerly Fundamental Applied Biology Inc, discovers, develops and manufactures novel cancer medicines which include antibody-drug conjugates (ADC’s), bispecific antibodies, and antibody-based therapeutics targeting immuno-oncology pathways. Its pipeline portfolio includes STRO-001, a CD74 ADC for the treatment of multiple myeloma, lymphomas, diffuse large B-cell lymphoma (DLBCL) and Mantle cell lymphoma (MCL); STRO-002, targeting ovarian and endometrial cancer. The company develops its pipeline products through Xpress CF platform, a biochemical protein synthesis system which develops therapeutic proteins and discovers drugs for the treatment and prevention of diseases. Sutro Biopharma owns a manufacturing facility in San Carlos, California. The company works in partnership with various pharmaceutical and biotechnology companies for pre-clinical development of novel antibody drug conjugates. Sutro Biopharma is headquartered in South San Francisco, California, the US.

Sutro Biopharma Inc (STRO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sutro Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Sutro Biopharma Raises USD85.4 Million in Series E Financing 11
Sutro Biopharma Raises USD60 Million in Venture Financing 13
SutroVax Raises Funds Through Initial Financing Round 14
Sutro Biopharma Raises US$26 Million In Series D Financing 15
Sutro Biopharma Raises US$16.5 Million In Second Tranche Of Series C Financing 17
Partnerships 19
Sutro Biopharma and Leukemia & Lymphoma Society Enter into Partnership 19
Sutro Biopharma Amends Co-Development Agreement with Celgene 20
Sutro Biopharma Enters into Agreement with University of California, San Francisco 22
Sutro Biopharma Enters Into Co-Development Agreement With Memorial Sloan-Kettering Cancer Center 23
Sutro Biopharma Enters Into Co-Development Agreement With Sanofi Pasteur 24
Sutro Biopharma Enters Into Co-Development Agreement With Celgene 25
Licensing Agreements 26
Merck Enters into Licensing Agreement with Sutro Biopharma 26
EnWave Enters into License Agreement with Sutro Biopharma for powderREV Technology 27
EMD Serono Enters into Licensing Agreement with Sutro Biopharma 28
Sutro Biopharma Enters Into Licensing Agreement With Scripps Research Institute For Click Chemistry 29
Equity Offering 30
Sutro Biopharma Prices IPO of Shares for USD85 Million 30
SutroVax Spins Out from Sutro Biopharma 31
Sutro Biopharma Inc – Key Competitors 32
Sutro Biopharma Inc – Key Employees 33
Sutro Biopharma Inc – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
Nov 14, 2018: Sutro Biopharma announces third quarter 2018 financial results 35
Corporate Communications 37
Nov 08, 2018: Sutro appoints industry veteran Shalini Sharp to board of directors 37
Sep 12, 2018: Sutro Biopharma names Worsley as Chief Business Officer and Linda Fitzpatrick as People and Communications Chief 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39

List of Tables
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sutro Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sutro Biopharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Sutro Biopharma Raises USD85.4 Million in Series E Financing 11
Sutro Biopharma Raises USD60 Million in Venture Financing 13
SutroVax Raises Funds Through Initial Financing Round 14
Sutro Biopharma Raises US$26 Million In Series D Financing 15
Sutro Biopharma Raises US$16.5 Million In Second Tranche Of Series C Financing 17
Sutro Biopharma and Leukemia & Lymphoma Society Enter into Partnership 19
Sutro Biopharma Amends Co-Development Agreement with Celgene 20
Sutro Biopharma Enters into Agreement with University of California, San Francisco 22
Sutro Biopharma Enters Into Co-Development Agreement With Memorial Sloan-Kettering Cancer Center 23
Sutro Biopharma Enters Into Co-Development Agreement With Sanofi Pasteur 24
Sutro Biopharma Enters Into Co-Development Agreement With Celgene 25
Merck Enters into Licensing Agreement with Sutro Biopharma 26
EnWave Enters into License Agreement with Sutro Biopharma for powderREV Technology 27
EMD Serono Enters into Licensing Agreement with Sutro Biopharma 28
Sutro Biopharma Enters Into Licensing Agreement With Scripps Research Institute For Click Chemistry 29
Sutro Biopharma Prices IPO of Shares for USD85 Million 30
SutroVax Spins Out from Sutro Biopharma 31
Sutro Biopharma Inc, Key Competitors 32
Sutro Biopharma Inc, Key Employees 33
Sutro Biopharma Inc, Other Locations 34

List of Figures
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sutro Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Sutro Biopharma Inc (STRO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Amazon.com Inc (AMZN):企業の財務・戦略的SWOT分析
    Amazon.com Inc (AMZN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • PSR Group BV:製薬・医療:M&Aディール及び事業提携情報
    Summary PSR Group BV (PSR) is a contract research and staffing consultancy service provider. The company operates through two divisions such as PSR Orphan Experts and PSR Pharma Resource. Its PSR Orphan Experts is a contract research organization that concentrates on orphan drug development. The com …
  • Wartsila Corp (WRT1V):電力:M&Aディール及び事業提携情報
    Summary Wartsila Corp (Wartsila) is a mechanical or industrial engineering company. It offers smart technologies and complete lifecycle solutions. Through sustainable innovation, total efficiency, and data analytics, the company harnesses the environmental and economic performance of the vessels and …
  • Range Resources Corporation:企業の戦略・SWOT・財務情報
    Range Resources Corporation - Strategy, SWOT and Corporate Finance Report Summary Range Resources Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Hoteli-Metropol AD Ohrid:企業の戦略・SWOT・財務情報
    Hoteli-Metropol AD Ohrid - Strategy, SWOT and Corporate Finance Report Summary Hoteli-Metropol AD Ohrid - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Wacker Chemie AG (WCH)-エネルギー分野:企業M&A・提携分析
    Summary Wacker Chemie AG (Wacker) develops, manufactures, and markets various chemical and semiconductor materials. It offers a range of silicone fluids and emulsions, resins, elastomers, sealants and silanes. The company manufactures binders and polymeric additives such as dispersible polymer powde …
  • Diagnostics For All Inc:企業の製品パイプライン分析
    Summary Diagnostics For All Inc (DFA) is a drug development company that develops and commercializes of new technology and practical diagnostic devices for diagnostic companies. The company uses patterned paper technology to create electrochemical clinical chemistry assays, immunoassays, assays, and …
  • Quest Diagnostics Inc (DGX):企業の財務・戦略的SWOT分析
    Quest Diagnostics Inc (DGX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Hostess Brands Inc (TWNK):企業の財務・戦略的SWOT分析
    Hostess Brands Inc (TWNK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Regis Corporation (RGS):企業の財務・戦略的SWOT分析
    Regis Corporation (RGS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Laboratorios Farmaceuticos Rovi SA (ROVI):企業の財務・戦略的SWOT分析
    Summary Laboratorios Farmaceuticos Rovi SA (Rovi) is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of prescription and hospital products. The company's product portfolio includes licensed prescription pharmaceuticals in the therapeutic areas of cardiovas …
  • Glu Mobile Inc (GLUU):企業の財務・戦略的SWOT分析
    Glu Mobile Inc (GLUU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • SMS Pharmaceuticals Ltd (SMSPHARMA):企業の財務・戦略的SWOT分析
    SMS Pharmaceuticals Ltd (SMSPHARMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Renova Energia SA (RNEW11)-エネルギー分野:企業M&A・提携分析
    Summary Renova Energia S.A. (Renova Energia) is a renewable power generation company. It develops, implements and operates power generation projects based on renewable energy sources such as wind, small hydropower and solar; and sells electricity. It also undertakes activities related to manufacturi …
  • Bergman & Beving AB:企業の戦略・SWOT・財務情報
    Bergman & Beving AB - Strategy, SWOT and Corporate Finance Report Summary Bergman & Beving AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Scynexis Inc (SCYX):企業の財務・戦略的SWOT分析
    Summary Scynexis Inc (Scynexis) is a pharmaceutical company that discovers, develops and commercializes novel anti-infective for various therapeutic needs. The company provides pipeline products such as SCY-078, is used for invasive fungal infections; SCY-635, is used for the treatment of Hepatitis …
  • GCL-Poly Energy Holdings Ltd:企業の発電所・SWOT分析2018
    GCL-Poly Energy Holdings Ltd - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Screen Holdings Co., Ltd. (7735):企業の財務・戦略的SWOT分析
    Screen Holdings Co., Ltd. (7735) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • JetBlue Airways Corp:企業の戦略・SWOT・財務情報
    JetBlue Airways Corp - Strategy, SWOT and Corporate Finance Report Summary JetBlue Airways Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Sojitz Corp (2768):電力:M&Aディール及び事業提携情報
    Summary Sojitz Corp (Sojitz) is a diversified general trading group. The group through its subsidiaries and affiliates holds interest in machinery; energy and metals; chemicals and functional materials; and consumer lifestyle businesses. It distributes automobiles and aircraft; develops power projec …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆